In Australia, published data on the etiology of CAP are limited [4] [5] [6] [7] . The most rigorous of these studies was published in 1989 and consisted of results for 106 patients at 1 hospital. The most common causes of CAP were Streptococcus pneumoniae (in 42% of cases), respiratory viruses (in 18%), Haemophilus influenzae (in 9%), Mycoplasma pneumoniae (in 8%), and gram-negative bacteria (in 8%) [4] . Some of the diagnostic tests used in this study are no longer in common use, and some criteria used for making diagnoses would no longer be accepted. The other studies also had major limitations [5] [6] [7] . This paucity of local data has led clinicians to rely on international studies, which may not necessarily be appropriate.
The Australian Community-Acquired Pneumonia Study (ACAPS) was a prospective, multicenter, observational study of immunocompetent adults with CAP. Its aim was to provide Australian data on CAP etiology, usefulness of severity assessment tools, and treatment outcomes. The etiology data from ACAPS forms the largest ever study of CAP etiology and is one of the few studies worldwide to assess CAP etiology using the full array of diagnostic methods, including bacterial cultures, urinary antigens, viral PCR, and acute-and convalescent-phase serologic tests [8] [9] [10] [11] . Blood specimens for culture-and, when possible, sputum specimens for Gram stain and culture-were obtained before receipt of parenteral antibiotics. Nose and throat swabs for respiratory virus PCR testing, standard nonconcentrated urine samples for pneumococcal and Legionella antigen testing, and acute-phase serum samples were collected at the time of recruitment within 48 h after hospital admission. At the time of patient follow-up (4-8 weeks after hospital discharge), convalescent-phase serum samples were obtained. Antibiotic therapy was given at the discretion of the treating clinician, although the hospitals involved were encouraging staff to follow the Australian guidelines (table 1) [2] . If patients did not attend followup appointments, they were telephoned by a study coordinator to assess 30-day mortality and cure and to arrange convalescent-phase serologic testing.
METHODS

Study
Microbiological studies. Aerobic and anaerobic blood cultures, as well as Gram stain and culture of sputum samples, were performed by conventional methods. PCR testing of the combined nose and throat swab samples was as described elsewhere for influenza A and B viruses, parainfluenza virus types 1-3, respiratory syncytial virus, adenoviruses, and picornaviruses [13] . Urine testing with the BinaxNOW pneumococcal [15] ). All relevant bacterial isolates, viral swabs, viral extracted DNA, serum specimens, and urine samples were stored. Viral and serologic tests that were performed in Brisbane and Perth were retested in Melbourne to ensure consistent results.
Classification of etiology. The etiology of CAP was determined to be definite if any of the following criteria were met: the organism was cultured from blood samples; urinary antigen tests were positive for S. pneumoniae or L. pneumophila; PCR of nose and throat swab samples yielded positive results; purulent sputum sample (presence of 125 polymorphonuclear leukocytes and ! 10 squamous cells per low-power field), with a predominant organism cultured and compatible results from Gram stain; presence of IgM antibodies for M. pneumoniae; or 4-fold increases in IgG antibody titers for M. pneumoniae, L. pneumophila, C. pneumoniae, C. psittaci, or influenza virus. Diagnosis was defined as "presumptive" if purulent sputum sample cultured a predominant organism but without compatible Gram stain or if serologic test titers did not meet the aforementioned criteria but were suggestive of recent infection [11] .
Outcome measures. The measured outcomes were etiology, antibiotic treatment received, time to "step down" from intravenous to oral antibiotics, time to clinical stability (defined as a temperature р37.2ЊC and a respiratory rate р24 breaths/min for 24 h) [16] , the need to "step up" to broader-spectrum antibiotics, length of stay, the need for intensive respiratory or vasopressor support (IRVS; defined as the use of mechanical ventilation via endotracheal intubation, noninvasive ventilation, or receipt of infusion of vasoactive agents) in the intensive care unit (ICU), and in-hospital and 30-day mortality rates. The PSI and CURB-65 scores were calculated for all patients, as described elsewhere [3, 17] . On the basis of CURB-65 scores, patients were classified in the following groups: group 1, scores of 0-1; group 2, score of 2; and group 3, scores of 3-5 [17] .
Statistical analysis. To detect differences between specified groups, either the x 2 test, Fisher's exact test, or the MannWhitney U test were used, as appropriate, with P values !.05 considered to be statistically significant. Statistical calculations were performed using Stata software (Intercooled Stata, version 9 for Windows; Stata Corporation).
RESULTS
Patient characteristics.
More than 2500 persons were assessed for possible study recruitment, with the major reason for exclusion being a chest radiograph finding that was either normal or inconsistent with CAP. Other reasons for exclusion were receipt of parenteral antibiotics prior to blood cultures, hospitalization within the preceding 2 weeks, a diagnosis of aspiration, receipt of palliative treatment, or lack of provided consent. Eight hundred sixty-five patients with a total of 885 episodes of CAP were recruited during the 28 months of the study, the majority of whom presented to 3 of the urban teaching hospitals. The demographic characteristics of patients are presented in table 2. The overall 30-day mortality rate was 5.6% Haemophilus (50 of 885 episodes). The mean age (‫ע‬SD) was 65.1 ‫ע‬ 19.9 years (range, 18-100 years). Etiology. Etiology was identified in 404 (45.6%) of 885 episodes, and 11 pathogen was isolated in 75 episodes (8.5%). Results are shown in table 3. The most common organisms were S. pneumoniae (14% of episodes) and M. pneumoniae (9%), but together, the respiratory viruses (influenza virus, picornaviruses, respiratory syncytial virus, parainfluenza virus, and adenovirus) were identified in 15% of episodes. In only 48 (5.4%) of 885 episodes was a pathogen found that would not be adequately treated with the combination of a penicillin plus either doxycycline or a macrolide, and many of the affected patients had significant risk factors to alert the clinician to their unusual pathogen (see "Associations between specific etiologies and comorbidities or age" below).
For the 123 episodes of pneumococcal CAP, the diagnosis was made by urinary antigen data alone in 58 episodes, sputum data alone in 20, both blood culture and urinary antigen data in 17, sputum and urinary antigen data in 12, blood culture data alone in 8, and all 3 tests in 8. Of the 33 episodes of bacteremic pneumococcal infection, 2 (6.1%) involved bacteria with intermediate susceptibility to penicillin (MIC, 1 mg/mL). There were no penicillin-resistant isolates in blood cultures. Of the 40 patients for whom sputum cultures yielded pneumo- ). Re-P p .36 spiratory viruses and a bacterial copathogen were detected in 47 episodes (5.3%), whereas a respiratory virus alone was noted almost twice as frequently (91 episodes [10.3%] ).
Associations between specific etiologies and comorbidities or age. Chronic obstructive pulmonary disease was the major comorbidity (12 of 16 episodes) for episodes in which aerobic, gram-negative bacteria (e.g., Pseudomonas species) were isolated. The majority of patients with pseudomonal infection were known to have been previously colonized.
Cultures yielded gram-negative enteric bacilli (GNEB; e.g., Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis) for patients from long-term care facilities or for those with extensive comorbidities. Eight patients had GNEB bacteremia, and for 4 of these 8 patients, urine cultures also yielded the same pathogen.
There was an association between legionellosis and a history of renal impairment ( ). Mycoplasma infection was as-P p .04 sociated with an age !50 years ( ). P ! .001 For the 55 episodes involving patients from nursing homes, the identified pathogens were respiratory viruses in 9 (16.4%), pneumococcus in 8 (14.5%; 1 isolate had intermediate susceptibility to penicillin, and all others were susceptible to penicillin), GNEB in 4 (7.3%), and H. influenzae in 2 (3.6%). This cohort had a high 30-day mortality rate (16 [29. 1%] of 55 episodes) but a low rate of IRVS requirement (3 episodes [5.5%]).
Outcomes associated with specific pathogens. A higher risk of IRVS requirement was associated with picornavirus infection ( ), but there were weaker associations with influenza P p .01 ( ), pneumococcus infection ( ), and legionellosis P p .05 P p .06 ( ). The mortality rate was higher for CAP due to Pseu-P p .09 domonas species than for other causes of CAP ( ), al-P ! .001 though this likely reflects the very poor premorbid conditions of patients for whom CAP was due to this organism.
Utility of sputum examination and blood culture. A sputum sample was obtained in 524 (59.2%) of 885 episodes, and the CAP diagnosis was established using sputum analysis in 103 (19.7%) of these 524 episodes (i.e., 103 [11.6%] of all 885 study episodes). Blood cultures identified a pathogen in 54 (6.2%) of 868 episodes, with S. pneumoniae being the most frequent isolate in 33 (61.1%). There was a likely contaminant in the blood cultures for an additional 36 (4.1%) of 868 episodes, the most common contaminant being coagulase-negative staphylococcal species. Blood culture results were more likely to be positive in patients who had not received prior oral antibiotics (44 of 604 vs. 10 of 264;
). P p .05 Treatment and outcome. Choice of antibiotic therapy was consistent with the recommendations of the Australian antibiotic guidelines in 729 episodes (82.4%). Simple b-lactam therapy (e.g., benzylpenicillin, amoxycillin, or ampicillin), in combination with either a macrolide or doxycycline, was given in 494 (55.8%) of 885 episodes (mean PSI score ‫ע‬ SD, 86 ‫ע‬ ). Ceftriaxone-based therapy was used in 326 (36.8%) of 885 56 episodes (mean PSI score ‫ע‬ SD, ). Penicillin allergy 112 ‫ע‬ 41 was documented in 102 (31.3%) of 326 episodes treated with ceftriaxone. Moxifloxacin was administered to 7 patients, all of whom had penicillin allergy. Of the 10 patients who had pneumococcal infection with reduced susceptibility, 5 were successfully treated with penicillin or amoxycillin; this included 1 patient whose sputum data indicated that the infection was resistant to penicillin and 1 patient whose blood culture indicated intermediate susceptibility to penicillin. The other 5 patients received ceftriaxone.
The 30-day mortality rate among patients who received penicillin-based therapy was lower than that among patients who received ceftriaxone-based therapy (3.8% vs. 8.6%), although patients with higher mortality risk (i.e., pneumonia severity index class V or treatment in an ICU) were more likely to receive ceftriaxone. Unadjusted outcomes of therapy are shown in table 5. A comparison of antibiotics used and outcomes based on whether an etiologic agent was identified is presented in table 6 .
DISCUSSION
This study is one of the largest prospective studies of the etiology of CAP ever performed. As expected, S. pneumoniae was the most common single organism, although it was identified at a rate lower than the 35%-75% rate that has been quoted in some previous studies [4, [18] [19] [20] . The decrease in relative frequency of identified pneumococcal cases of CAP has been described elsewhere, although the reasons for this decrease are not clear [21] ; possibilities include pneumococcal vaccination programs, increased preadmission treatment with oral antibiotics, and a decrease in the quality of sputum testing by laboratory staff. However, the pneumococcal urinary antigen test may help detect patients with false-negative sputum or blood culture results [22] .
An important finding was the relatively high frequency of PCR-detected respiratory viruses, both as sole pathogens and among all categories of CAP severity, including among patients who required IRVS. Also notable was the low number of cases (4% overall) caused by GNEB, Pseudomonas species, or S. aureus, even among patients with more severe CAP. Many of these episodes were potentially predictable on the basis of prior colonization or presence of extensive comorbidities.
Certain organisms were associated with more severe CAP: S. pneumoniae, influenza virus, and picornavirus were found more frequently in patients who required IRVS. Cases of legionellosis, although not common, generally involved L. pneumophila (83%); only 3 were cases due to Legionella longbeachae. Outcomes were not significantly worse for patients with legionellosis than for those with CAP due to other pathogens.
These etiology results suggest that broad-spectrum antibiotics are not necessary for the vast majority of Australian patients with CAP. Only 5.4% of episodes involved isolation of a pathogen with in vitro resistance to benzylpenicillin plus either doxycycline or a macrolide. The likely etiology of CAP was pneumococcal, viral, or "atypical," even for the 94 patients who required IRVS, with only 7 cases (7.4%) due to more resistant organisms (e.g., Pseudomonas species, GNEB, or S. aureus). Our 30-day mortality data and rate of IRVS are comparable with those in international studies of hospitalized patients, even though the majority of patients in ACAPS received a narrow-spectrum penicillin combined with either doxycycline or a macrolide [3, 17, 23] . One-half of the patients who were infected with pneumococcal isolates with reduced penicillin susceptibility were cured with benzylpenicillin or amoxycillin, as has been reported by others [24] . The antibiotics used and outcomes were similar regardless of whether patients had a pathogen isolated.
Our finding that antibiotic-resistant pathogens were infrequent causes of CAP contrasts starkly with laboratory-based studies that have assessed resistance rates among consecutive bacterial isolates, as opposed to consecutive patients with CAP. Although our data suggest a low prevalence of pneumococcal resistance in Australia, a previous laboratory-based study found that 125% of consecutive pneumococcal isolates were classified as penicillin nonsusceptible [25] . In the absence of data from clinical studies similar to ours, it is possible that other nations may have also overestimated the likely rates of resistance among patients with CAP.
Numerous authors and international CAP management guidelines-including the most recent guidelines from the United States [26] -have promoted the use of "respiratory" fluoroquinolones (e.g., moxifloxacin). However, prospective studies comparing these agents with combination therapy containing a b-lactam and a macrolide have shown equivalence [27, 28] . Similarly, other studies that compared fluoroquinolones with a b-lactam plus the discretionary use of a macrolide have also shown equivalence [29] [30] [31] [32] [33] , with only 1 exception [34] . The increased rate of resistance observed with the widespread use of these drugs is cause for concern, and unlike for benzylpenicillin, treatment failures among patients with pneumococcal CAP or bacteremia have been reported [35] [36] [37] [38] [39] [40] [41] . The use of fluoroquinolones has also been associated with infections due to clinically aggressive strains of Clostridium difficile [42] and extended-spectrum b-lactamase-producing gram-negative bacilli [43] . Thus, considering the availability of many other antibiotics with equivalent efficacy for treatment of CAP, it would seem to be prudent to avoid the widespread use of fluoroquinolones for this indication. Given the paucity of new antibiotics in development, any measures to prolong the useful lifespan of antibiotic classes, such as the fluoroquinolones, should be encouraged [44] .
Our study has some limitations, including the fact that the majority of patients were inpatients recruited from 3 large, urban tertiary care referral centers. Therefore, we cannot be sure that our data can be generalized to other settings (e.g., primary care settings), to significantly immunosuppressed patients, or to patients with hospital-acquired pneumonia (who were excluded from ACAPS). Similar to other studies, we noted that, among patients who had recently received oral antibiotics, sputum specimens were of limited diagnostic utility-a finding that may explain why no etiology was identified in more than one-half of our patients [45] . Paired serum samples were not obtained from 24% of patients, and nose and throat swab samples for viral testing were not obtained from 13%. With regard to treatment outcomes, this was an observational study, with antibiotic choices made by the treating clinician; thus, there is no control group for comparison.
Despite these limitations, ours is the most significant study of CAP etiology in Australia, with the study population consisting of patients with CAP rather than sequential bacterial isolates. Strong supportive evidence for the use of narrowspectrum b-lactam antibiotics, combined with either doxycycline or a macrolide, for treatment of CAP is provided by the low frequency of antibiotic-resistant pathogens and the good 30-day mortality rates and rate of IRVS requirement. Because CAP is such a frequent indication for antibiotic prescribing, greater use of such agents has the potential to have a significant impact on antibiotic selection pressure exerted by often more expensive and broader-spectrum drugs, such as fluoroquinolones.
